An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy
Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Feb 16, 2022
Trial Information
Current as of May 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. pathological diagnosis of invasive breast cancer
- • 2. breast surgery within the past 2-8 weeks
- • 3. adult female
- • 4. must be able to use mobile phones
- • 5. speak and write Chinese fluently to sign the informed consent
- Exclusion Criteria:
- • 1. severe comorbidity that interferes with outcome evaluation
- • 2. insufficient Chinese language skills
- • 3. inability to use mobile phones
- • 4. cognitive disability to give informed consent
About Peking Union Medical College Hospital
Peking Union Medical College Hospital (PUMCH) is a prestigious medical institution and a leading research facility located in Beijing, China. Affiliated with the Chinese Academy of Medical Sciences, PUMCH is renowned for its commitment to advancing healthcare through innovative clinical research and high-quality patient care. The hospital plays a pivotal role in the development and execution of clinical trials across various medical disciplines, focusing on improving treatment outcomes and enhancing medical knowledge. With a multidisciplinary team of experts and state-of-the-art facilities, PUMCH is dedicated to contributing to global health advancements and fostering collaborations in the medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Yan Li, Doctor
Study Director
Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials